Navigating the Implications of CMS’s Updated eCQM Requirements for Healthcare Providers

In an ever-evolving healthcare landscape, the role of electronic Clinical Quality Measures (eCQMs) in optimizing patient outcomes, streamlining operations, and ensuring regulatory compliance is paramount.

Read More

Healthcare Fundings

The recent investment and developmental strides in the #healthcare and #biotechnology sectors highlighting key startups and their #funding rounds, as well as significant corporate partnerships and setbacks:

Apollo Therapeutics , a UK-based startup with seven years of operation, uses medical research to create therapies for #cancer, major inflammatory conditions, and rare diseases. The company has successfully raised $226.5 million in a Series C funding round spearheaded by Patient Square Capital . Other notable investors include M&G Investments , Rock Springs Capital , and two undisclosed pension plans. Thus far, the company has secured $421.5 million in funding.

Cambridge, Massachusetts-based Nimbus Therapeutics , a 14-year-old firm specializing in creating innovative small molecule cancer therapies, has garnered $210 million in a recent funding round. The investment was co-led by GV (Google Ventures) , SR One Capital Management , and Atlas Venture , all previous investors. To date, the company has amassed $637 million in funding.

Cambridge, Massachusetts-based startup Mariana Oncology, which focuses on creating radiopharmaceuticals for treating small cell lung cancer, has successfully garnered $175 million in a Series B funding round. Deep Track Capital and Forbion co-led the investment, with additional contributions from Nextech Invest , Surveyor Capital , 礼来 , and returning investors Atlas Venture , Access Biotechnology, and RA Capital Management . To date, the company has amassed $250 million in funding.

Palo Alto-based Inceptive , a four-year-old #biotech startup founded by former Google AI expert Jakob Uszkoreit , has secured $100 million in funding. The investment comes from 英伟达 and Andreessen Horowitz . The company specializes in developing novel vaccines and drugs and works on "biological software" that utilizes #AI technology. This approach was pioneered by founder Jakob Uszkoreit, who also co-authored a seminal paper that fueled advancements in generative AI, including technologies like #ChatGPT.

Based in La Jolla, California, Arialys Therapeutics, Inc. , a startup focused on developing neuropsychiatric medications and operating for just one year, has successfully garnered $58 million in seed funding. The investment round featured contributions from Avalon BioVentures , Catalys Pacific , MPM BioImpact , Johnson & Johnson Innovation JJDC Inc , and Alexandria Venture Investments.

Tel Aviv-based Ibex Medical Analytics , a seven-year-old startup specializing in AI-driven cancer diagnostics, has secured $55 million in a Series C investment round. The funding was led by 83NORTH and saw additional contributions from Sienna Venture Capital and existing investors Octopus Ventures , aMoon Fund , Planven , and Dell Technologies Capital . To date, the company has accumulated $118.5 million in funding.

San Francisco-based startup Noetik , which claims to have developed a multimodal tissue profiling platform that merges self-supervised learning and spatial biology to address core issues in cancer immunology, has successfully raised $14 million in a seed funding round. The investment was spearheaded by DCVC and included contributions from Zetta Venture Partners , 11.2 Capital , Catalio Capital Management , EPIC Ventures , Intermountain Ventures , North South Ventures , CJNV BioVentures, and Hummingbird Nomads Fund.

With nine years under its belt, Dutch startup Thirona , which specializes in using AI for thoracic CT image analysis, has raised $8 million in a funding round. HERAN Partners and the Borski Fund were the key investors in this financial endeavor.

Four years into its journey, Palm Beach-based DeLorean AI has secured $7.55 million in a Series A funding round. Specializing in leveraging #artificialintelligence to offer critical and cost-efficient health insights to medical providers and insurance firms, the startup attracted investment primarily from Sopris VC, Pinta Capital Partners , and James Chow. To date, the company has amassed $10.5 million in funding.

Tel Aviv-based Scala Biodesign , a startup specializing in enhancing drug efficacy by modifying them at the molecular level, has secured $5.5 million in seed funding. TLV Partners led the investment round.

Two years after its inception, San Francisco-based Glass Health has successfully raised $5 million in a seed funding round. The startup, which is developing an AI tool and LLM designed to recommend medical diagnoses, drew investment led by Initialized Capital . Additional contributions came from Tom Lee, the founder of One Medical , and epocrates and Galileo Healthcare Technologies .

In operation for just a year, Minneapolis-based GEM HEALTH , a startup offering virtual specialty care for sleep apnea patients, has secured $5 million in a seed funding round. HealthTrend Capital led the investment, and Mairs & Power Venture Capital and previous investor Base10 Partners made additional contributions.

Three years into its operation, New York-based startup Blooming Health , specializing in using AI to offer personalized healthcare solutions for older adults, has secured $4.2 million in seed funding. The investment round was co-led by Afore Capital and Crossbeam Venture Partners , with additional contributions from Metrodora Ventures and Evan Moore.

Other Noteworthy News

Moderna has entered into an extensive, multiyear partnership with German biotech firm Immatics , committing up to $1.8 billion to co-develop cancer treatments using messenger RNA and other advanced technologies. Bloomberg notes that Moderna has been exploring additional applications for its rapidly developed mRNA technology initially used for effective COVID-19 vaccines. Cancer represents one of the most promising avenues for this technology. Moderna is also collaborating with 默克 on a personalized cancer #vaccine targeting melanoma and other types of tumors, although #clinicaltrials could take years to finalize.

Four-year-old Neumora Therapeutics, specializing in developing medications for brain diseases and backed by Amgen and ソフトバンク , aims for a valuation as high as $2.74 billion in its upcoming U.S. IPO. According to its filing, the company plans to offer 14.7 million shares priced between $16 and $18 each, which could raise up to $264.8 million if sold at the higher end of the range. Besides Amgen and SoftBank, other significant shareholders in Neumora Therapeutics include ARCH Venture Partners and Biomatics Capital Partners LP .

ACELYRIN, INC. , a biotech firm that secured over $500 million in an IPO earlier this year, encountered its first significant hurdle today. The company's investigational anti-inflammatory drug, izokibep—a subcutaneous treatment intended for patients suffering from hidradenitis suppurativa, a prevalent skin disease causing abscesses and scars—failed to meet the primary objective in a crucial clinical trial. According to STAT, after 16 weeks of administering izokibep, there was no significant improvement in patients compared to those who received a placebo, thus not meeting the study's primary endpoint.